Published in Exp Dermatol on April 01, 2003
Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol (2010) 1.84
Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol (2011) 0.94
Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med (2013) 0.87
Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis. Dermatol Res Pract (2013) 0.75
In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44
Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12
Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95
How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87
The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77
Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73
Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71
Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62
Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J Allergy Clin Immunol (2011) 1.62
Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56
Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55
Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41
UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40
Interleukin-17 in inflammatory skin disorders. Curr Opin Allergy Clin Immunol (2007) 1.30
Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22
Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22
Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14
Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem (2007) 1.10
Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09
The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07
Overview of psoriasis. Dermatol Ther (2004) 1.04
Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04
Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97
Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol (2013) 0.95
Cutting edge: virus selectively primes human langerhans cells for CD70 expression promoting CD8+ T cell responses. J Immunol (2011) 0.93
T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92
Intradermally administered TLR4 agonist GLA-SE enhances the capacity of human skin DCs to activate T cells and promotes emigration of Langerhans cells. Vaccine (2012) 0.92
Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res (2005) 0.91
Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.90
Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90
Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89
T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res (2004) 0.89
Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res (2009) 0.89
Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol (2003) 0.89
The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89
Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88
Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88
Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol (2008) 0.87
Etanercept: an overview of dermatologic adverse events. Arch Dermatol (2011) 0.87
The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol (2009) 0.86
Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol (2004) 0.86
Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol (2011) 0.86
Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 0.85
Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol (2002) 0.83
Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83
High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83
Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med (2010) 0.82
Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. Contact Dermatitis (2013) 0.82
Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res (2004) 0.82
Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat (2011) 0.82
Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res (2007) 0.82
Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol (2008) 0.82
Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol (2006) 0.82
Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. Exp Dermatol (2008) 0.82
Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol Immunol (2005) 0.81
Intradermal application of vitamin D3 increases migration of CD14+ dermal dendritic cells and promotes the development of Foxp3+ regulatory T cells. Hum Vaccin Immunother (2013) 0.81
Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol (2002) 0.80
Tertiary teledermatology: a systematic review. Telemed J E Health (2010) 0.80
In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol (2004) 0.80
Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.79
Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol (2004) 0.79
Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol (2009) 0.79
Lichen planus remission is associated with a decrease of human herpes virus type 7 protein expression in plasmacytoid dendritic cells. Arch Dermatol Res (2007) 0.79
Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther (2012) 0.79
Epidermal cis-urocanic acid levels correlate with lower specific cellular immune responses after hepatitis B vaccination of ultraviolet B-exposed humans. Photochem Photobiol (2003) 0.78
Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol (2010) 0.78
Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol (2008) 0.77
Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol (2006) 0.77
Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. Arch Dermatol (2004) 0.77
UVB irradiation of normal human skin favors the development of type-2 T-cells in vivo and in primary dermal cell cultures. Photochem Photobiol (2002) 0.77
Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol (2004) 0.77
The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol (2004) 0.76
A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology (2012) 0.76
Filaggrin loss-of-function mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study. Contact Dermatitis (2013) 0.76
Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat (2007) 0.76
Smallpox: what the dermatologist should know. Skinmed (2004) 0.76
The atopic epidemic and the humidity hypothesis. J Cosmet Dermatol (2004) 0.75
The use of patch tests in determining hypersensitivity to etanercept and infliximab. Arch Dermatol (2008) 0.75
Proliferating prevalence of concepts and controversies in atopic eczema. J Cosmet Dermatol (2004) 0.75
Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ. Arch Dermatol Res (2002) 0.75
A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists. J Telemed Telecare (2010) 0.75
Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Exp Dermatol (2010) 0.75